KRAS and cancer: TF expression in cancer can be upregulated by mutations in the tumor suppressor gene TP53 and the proto-oncogene KRAS, which activate the mitogen-activated protein kinase (MAPK) and PI3/AKT signaling pathways, subsequently leading to the upregulation of TF on cancer cells [80].